NYSE:HSY
NYSE:HSYFood

Reassessing Hershey (HSY) Valuation After Morgan Stanley Upgrade and Renewed Earnings Growth Expectations

Morgan Stanley’s upgrade just put Hershey (HSY) back on a lot of radar screens, as easing cocoa costs and a clearer path to earnings growth into 2026 reshape how investors are valuing this classic consumer name. See our latest analysis for Hershey. The upgrade comes after a choppy year, where a recent 1 month share price return of about 5 percent and 7 day share price return just over 4 percent hint that momentum is rebuilding, despite a slightly negative 3 month share price return and a...
NYSE:CLVT
NYSE:CLVTProfessional Services

Clarivate (CLVT): Assessing the Valuation After New AI Tools Boost Its Research and IP Platform

Clarivate (CLVT) just rolled out two new AI driven tools, the Cortellis Regulatory Intelligence AI Assistant and Derwent Patent Monitor, in moves that underline its push to make research and IP workflows faster and more decision ready. See our latest analysis for Clarivate. Those launches land at an interesting moment, with Clarivate’s 1 day share price return of 3.21 percent offering a brief lift against a much weaker year to date share price return of negative 31.26 percent and a five year...
NasdaqGS:CMCSA
NasdaqGS:CMCSAMedia

US Stock Market Today: S&P 500 Futures Rise amid Cooling Costs, Resilient Housing Data

The Morning Bull - US Market Morning Update Tuesday, Dec, 16 2025 US stock futures are pointing higher this morning, with contracts tied to the S&P 500 up about half a percent, as investors weigh cooling but still elevated business costs against signs of resilience in housing. The latest New York manufacturing survey slipped back into contraction at minus 3.9, which means factories in that region are pulling back a bit, but it also showed that price pressures are easing, a mild positive for...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Why Praxis Precision Medicines (PRAX) Is Up 7.1% After FDA Alignment On 2026 NDA Path

In recent days, Praxis Precision Medicines reported positive clinical outcomes for its EMBOLD study of relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies, alongside FDA alignment on an early 2026 New Drug Application submission and a streamlined, single-arm EMBRAVE3 registrational study for elsunersen in SCN2A-DEE. Taken together, these updates position Praxis as a rare neurology company advancing both a potential first-in-class small molecule and an antisense...
NYSE:BABA
NYSE:BABAMultiline Retail

Alibaba Group Holding (NYSE:BABA): Assessing Valuation After Recent Share Price Pullback

Alibaba Group Holding (NYSE:BABA) has quietly slipped about 4% over the past week and 7% in the past 3 months, even as its year to date return still sits near 77%. See our latest analysis for Alibaba Group Holding. That pullback comes after a powerful run, with the 1 year total shareholder return still above 77% and the latest share price at $150.09. This suggests momentum is cooling a little as investors reassess how much near term growth and regulatory risk are already priced in. If...
NYSE:NUVB
NYSE:NUVBPharmaceuticals

Is Nuvation Bio’s 228.6% 2025 Surge Still Supported by Valuation?

If you are wondering whether Nuvation Bio's explosive run means you are late to the party or looking at a genuine opportunity, let's break down what the current price might really be worth. The stock has been on a tear recently, with a 75.1% gain over the last month and a 228.6% jump year to date, even after a small 0.8% pullback over the past week. That surge has been fueled by growing optimism around Nuvation Bio's oncology pipeline and increasing investor attention on small cap biotech...
NasdaqGM:VERI
NasdaqGM:VERISoftware

Veritone (VERI): Assessing Valuation After New AI Partnerships in Digital Evidence and Edge-to-Enterprise Data Workflows

Veritone (VERI) has been on traders radar after a flurry of AI focused deals, from powering Strategic Communications JPS TRUST modernization program to teaming with Armada on edge to enterprise data workflows. See our latest analysis for Veritone. Despite a sharp pullback in the latest session, with a 1 day share price return of minus 8.79 percent and the stock closing at 5.19 dollars, Veritone still shows strong positive momentum. This is supported by a 30 day share price return of 20.70...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Halozyme Therapeutics (HALO): A Fresh Look at Valuation After Board Appointment of Dealmaker Jim Lang

Halozyme Therapeutics (HALO) just added seasoned healthcare dealmaker Jim Lang to its board, and that move has investors asking whether fresh strategic eyes could help unlock more value after a mixed few months for the stock. See our latest analysis for Halozyme Therapeutics. The timing is interesting, as Halozyme’s share price sits at 63.45 dollars after a solid year to date share price return of just over 32 percent. However, the 3 year total shareholder return is a more modest 12 percent,...
NYSE:AMBP
NYSE:AMBPPackaging

Assessing Ardagh Metal Packaging (NYSE:AMBP) After Upgraded Earnings Forecasts and Strong Recent Share Price Outperformance

Recent upgrades in analyst sentiment toward Ardagh Metal Packaging (NYSE:AMBP), including a 5.9% upward move in full year earnings estimates and clear share price outperformance this year, have put the stock back on investor radar. See our latest analysis for Ardagh Metal Packaging. The recent upgrades seem to be feeding into performance, with a roughly 42% year to date share price return and a 49.6% one year total shareholder return signaling that momentum is building rather than fading. If...
NasdaqGS:FFBC
NasdaqGS:FFBCBanks

Assessing First Financial Bancorp’s Valuation After Recent Share Price Gains and Strategic Expansion

Recent Performance Puts First Financial Bancorp in Focus First Financial Bancorp (FFBC) has quietly outpaced many regional peers, with the stock up about 4% over the past week, 12% over the past month, and 6% in the past 3 months. See our latest analysis for First Financial Bancorp. That short term strength sits against a more muted backdrop, with the share price now at $26.98, a modest year to date share price return but a solid multi year total shareholder return suggesting momentum may be...
NasdaqGS:AVGO
NasdaqGS:AVGOSemiconductor

Is It Too Late To Consider Broadcom After AI Surge And VMware Acquisition?

If you are wondering whether Broadcom is still a smart buy after its huge multi year run, or if you might be late to the party, this breakdown is for you. The stock has had a choppy stretch, falling 16.4% over the last week and slipping 0.8% over the past month, but it is still up 46.5% year to date and 770.5% over five years, which keeps it firmly on growth focused investors' radar. Much of this momentum has been driven by Broadcom's central role in AI infrastructure and high performance...
NYSE:ADM
NYSE:ADMFood

Does ADM’s 20% 2025 Rally Still Leave Room for Long Term Upside?

If you have been wondering whether Archer-Daniels-Midland is still a value play or if the market has already priced in the upside, you are not alone. This stock sits at the crossroads of defensive staple and cyclical opportunity. After a choppy few years, the share price has quietly put together a solid run, up 3.9% over the last week, 2.7% over the past month, and roughly 20% year to date, while still sitting well below its levels from three years ago. Recent headlines around global grain...
NYSE:TTI
NYSE:TTIEnergy Services

The Bull Case For TETRA Technologies (TTI) Could Change Following Evergreen Magnesium JV Plan With Magrathea

Earlier this month, TETRA Technologies, Inc. announced a term sheet to form a joint venture with Magrathea Metals, Inc. to integrate clean magnesium production into its Evergreen bromine and critical minerals project in Southwest Arkansas, targeting domestic supply for defense and industrial uses. This planned collaboration not only broadens TETRA’s exposure to critical minerals like magnesium, lithium, and bromine, but also links the Evergreen Project directly to U.S. supply-chain and...